Catalent says the $200 million it will spend over three years to expand drug substance manufacturing capacity and drug product fill/finish capacity in Bloomington, IN, and Madison, WI, reflects a commitment to expand further its fast-growing biologics business.
Work has begun at both sites, with completion expected in mid-2021. The provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products cited projected growth among existing and future customer in announcing the expansion this week.
“We’re still seeing strong growth in demand for development and production of proteins and monoclonal antibodies,” Michael . . .